(USD) | Mar 2024 | Q/Q |
---|---|---|
Revenue | 354MM | +1% |
Gross Profit | -31.1MM | - |
Cost Of Revenue | 385.1MM | +7% |
Operating Income | 72.3MM | -35% |
Operating Expenses | -103.5MM | - |
Net Income | 65MM | -28% |
G&A | 115.9MM | +15% |
Interest Expense | 425K | +24% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
EHC vs. CHE: Which Stock Is the Better Value Option?
Chemed Corporation (NYSE:CHE) Q1 2024 Earnings Call Transcript April 25, 2024 Chemed Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to the Chemed Corporation First Quarter 2024 Earnings Conference Call. […]
Chemed ( NYSE:CHE ) First Quarter 2024 Results Key Financial Results Revenue: US$589.2m (up 5.2% from 1Q 2023). Net...
Chemed Reports 'Soft' Q1 as Roto-Rooter Continues to Face Pressure, Oppenheimer Says
Chemed Corporation ( NYSE:CHE ) shareholders are probably feeling a little disappointed, since its shares fell 4.0% to...
Explore key insights from Chemed Corp's Q1 2024 earnings, including significant growth in VITAS services and challenges faced by Roto-Rooter.
Q1 2024 Chemed Corp Earnings Call
Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.
Chemed (CHE) delivered earnings and revenue surprises of -4.94% and 0.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Chemed Meets Revenue Projections But Sees Divergent Segment Performances